ClinicalTrials.Veeva

Menu

Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices) (GENUS)

M

Massachusetts Institute of Technology (MIT)

Status and phase

Enrolling
Phase 2

Conditions

Alzheimer Disease
Cognitively Healthy People

Treatments

Device: Tactile GENUS
Device: GENUS

Study type

Interventional

Funder types

Other

Identifiers

NCT07496918
Aging Brain Initiative (Other Identifier)
1712179268

Details and patient eligibility

About

Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.

Full description

Information processing in the brain is thought to occur through synchronized neuronal activity in the form of network oscillations. Activity in the 30-100 Hz range is considered gamma-band oscillation and has been reported to be critical for attention, memory formation, and recall. Disruptions of gamma oscillations, particularly in the 30 - 50 Hz range, are reported as a potential early hallmark of Alzheimer's disease.

40Hz gamma frequency stimulation was previously shown to reduce Alzheimer's disease pathology and improve cognitive outcomes. This study aims to:

  1. Determine whether non-invasive 40Hz sensory stimulation (ie, light, sound, tactile) can change brain activity.
  2. Evaluate whether devices delivering non-invasive 40Hz sensory stimulation are safe in cognitively normal adults.
  3. Determine whether non-invasive 40Hz sensory stimulation can change brain connectivity, neuropsychological measures, blood biomarkers, and the microbiome.

Enrollment

150 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Have adequate visual and auditory acuity for visual and auditory stimulation to allow for neuropsychological testing.
  • Be able to comply with neuropsychological testing and other study procedures in opinion of site PI.

Exclusion Criteria: Participants will be screened for the following exclusion criteria including if they

  • History of seizure or medical diagnosis of epilepsy.
  • Have MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.
  • Under the discretion of the site investigator, the site investigator feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Sequential Assignment

Masking

None (Open label)

150 participants in 1 patient group

Cognitively normal adults
Experimental group
Description:
Cognitively normal, healthy adults aged 18 - 100
Treatment:
Device: GENUS
Device: Tactile GENUS

Trial contacts and locations

1

Loading...

Central trial contact

gamma wave; Ana Trisini Lipsanopoulos, BS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems